ORIC Pharmaceuticals Inc.

ORIC® Chief Financial Officer Dominic Piscitelli and Chief Business Officer Matt Panuwat will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 8:00 a.m. ET. Listen to the live or archived discussion to learn the latest company updates here: https://bit.ly/3VxP4tj

This #NationalCancerSurvivorsDay, we honor the strength, resilience, and journeys of cancer survivors everywhere. At ORIC®, our mission to Overcome Resistance In Cancer is rooted in the belief that patients deserve better, more durable treatment options. We remain committed to advancing innovative therapies designed to address one of the greatest challenges in cancer care and expand what’s possible for patients. 

ORIC® President and Chief Executive Officer Jacob Chacko, M.D., and Chief Financial Officer Dominic Piscitelli will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 11:40 a.m. ET. Listen to the live or archived discussion here: https://bit.ly/3VxP4tj

This AANHPI Heritage Month, we celebrate the theme, “Power in Unity: Strengthening Communities Together.” Asian American, Native Hawaiian, and Pacific Islander communities continue to make profound contributions to science and medicine, advancing discoveries that have transformed patient care. At ORIC®, we’re proud to celebrate these contributions and the role diverse perspectives play in driving innovation forward, because stronger science starts with a broader range of voices and experiences. #AANHPIHeritageMonth #PowerInUnity #DiversityInSTEM #Biotech #Innovation

This National Cancer Research Month, we’re #UnitedByCancerResearch, because progress depends on collective commitment, bold thinking, and continued investment in innovation. Treatment resistance remains one of the biggest barriers to durable clinical benefit. At ORIC®, we’re focused on developing therapies designed to Overcome Resistance In Cancer and expand what’s possible for patients. We aim to discover and develop new treatments to deliver better outcomes for those who need them most. #CancerResearchMonth #Oncology #Biotech #Innovation

Q1 2026 marked continued momentum for ORIC®, highlighted by rinzimetostat dose optimization data supporting a potential best-in-disease profile and the selection of the RP3D for our first Phase 3 trial in metastatic castration-resistant prostate cancer (mCRPC), Himalayas-1. With a strong cash position and multiple rinzimetostat and enozertinibupdates expected in 2H 2026, we are well-positioned to transition into a diversified late-stage company with potentially multiple Phase 3 opportunities. Explore our latest progress and what’s next here: https://bit.ly/42izTKi

Tomorrow, ORIC® Vice President, Head of Biology Melissa R Junttila, Ph.D., and Director, Head of Bioinformatics Alex Pankov, Ph.D., will present posters at #AACR2026 highlighting preclinical data demonstrating rinzimetostat’s potential as a differentiated treatment option for patients with prostate cancer. Be sure to stop by the poster session if you’re attending the meeting. 

Cancer Control Month is a reminder that progress in cancer care requires more than awareness, it takes continued innovation, early detection, and a commitment to addressing the challenges that limit treatment success. At ORIC®, we are working to Overcome Resistance In Cancer by developing therapies designed to address the mechanisms that enable disease to persist. Because improving outcomes starts with tackling what stands in the way. #CancerControlMonth

Today, we reported Phase 1b data for rinzimetostat in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC), highlighting its potential best-in-disease profile. These data support advancing the combination into Phase 3 registrational trials. Join our webcast at 4:30 p.m. ET today for a detailed review and program update: https://bit.ly/3VxP4tj Press release: https://lnkd.in/gY7wSVtB

We are pleased to share that two preclinical abstracts reinforcing the best-in-class potential of rinzimetostat (ORIC-944), our potent and selective allosteric inhibitor of PRC2, to treat prostate cancer have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026. Learn more here: https://bit.ly/40CeXx6 #AACR2026